Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1398 articles about Regeneron Pharmaceuticals, Inc.
-
Facing Tough Competition from Regeneron and Amgen, Aegerion Slashes 25% of Workforce
2/12/2016
-
Regeneron Reports Fourth Quarter And Full Year 2015 Financial And Operating Results
2/9/2016
-
Regeneron, Cellectis, Flagship Ventures And Others Headline NewYorkBIO 2016 CEO Breakfast Club Series
2/8/2016
-
Regeneron Stock Rocks, but Vertex, Medivation & Jazz Pharma Roll
2/4/2016
-
Kymab Succeeds In Revoking Regeneron’s UK VelocImmune Patents
2/2/2016
-
As Eylea and Praluent Sales Take Off, Regeneron Plans to Expand HQ and Manufacturing Sites
2/1/2016
-
Regeneron To Report Fourth Quarter And Full Year 2015 Financial And Operating Results And Host Conference Call And Webcast On February 9, 2016
1/26/2016
-
Regeneron Investors Get Jitters From False Praluent Data
1/8/2016
-
Regeneron And Sanofi Announce Sarilumab Biologics License Application Accepted For Review By US FDA
1/8/2016
-
Regeneron Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference
1/7/2016
-
Regeneron Mourns Passing Of Dr. Alfred G. Gilman, Board Member And Nobel Laureate
12/28/2015
-
Sanofi And Regeneron Announce UnitedHealth Group Selects Praluent (alirocumab) Injection For Preferred Access
12/11/2015
-
Robert G. Urban, PhD, Head Of Johnson & Johnson Innovation, Boston, And Hala Mirza, Vice President, Corporate Communications, Regeneron, Join NewYorkBIO Board Of Directors
12/7/2015
-
Regeneron And Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial Of Praluent Injection Fully Enrolled
11/24/2015
-
ERS Genomics Licenses Genome-Editing Patents To Regeneron
11/24/2015
-
CVS Picks Amgen's Repatha Over Sanofi-Regeneron's Cholesterol Drug
11/23/2015
-
Booming Regeneron to Add 300 New Jobs in New York Following $150 Million Expansion
11/16/2015
-
Sanofi And Regeneron Announce New Praluent (alirocumab) Injection Analyses Presented At American Heart Association Scientific Sessions 2015
11/11/2015
-
Regeneron And Sanofi Present Results From Pivotal Phase 3 Study Of Sarilumab At American College of Rheumatology Annual Meeting
11/9/2015
-
Sanofi And Regeneron To Present Results From Phase 3 Praluent (alirocumab) Injection Clinical Trials At American Heart Association Scientific Sessions 2015
11/5/2015